Buspirone in the treatment of posttraumatic stress disorder.
Three patients with a DSM-III-R diagnosis of posttraumatic stress disorder were successfully treated with buspirone in final maximum dosages ranging from 35-60 mg daily. The onset of clinical efficacy ranged from 5-29 days. Symptoms that improved included anxiety, insomnia, flashbacks, and depressed mood. Patients experienced no side effects. Serotonin partial agonist effects are a possible mechanism underlying buspirone's efficacy.
Department of Clinical Pharmacy, University of Tennessee, Memphis.
B G
BG
Wells
C C
CC
Chu
R
R
Johnson
C
C
Nasdahl
M A
MA
Ayubi
E
E
Sewell
P
P
Statham
D000368:Aged; D001007:Anxiety / Q000209:etiology; D002065:Buspirone / Q000008:administration & dosage / Q000627:therapeutic use*; D003863:Depression / Q000209:etiology; D004325:Dreams; D006801:Humans; D008297:Male; D008875:Middle Aged; D007319:Sleep Initiation and Maintenance Disorders / Q000209:etiology; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy* / Q000523:psychology
D002065:Buspirone